Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label abrocitinib study in pediatric moderate-to-severe atopic dermatitis
2023-509124-18-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Primary endpoint: Overall treatment-emergent adverse events. Planned start Aug 2025; status: authorised.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-509124-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509124-18-00.